High Presence in Priority Therapeutic Areas
High specialty and competitiveness in the three areas of internal medicine, obstetrics and gynecology, and urology
ASKA Pharmaceutical has a high degree of specialty and competitiveness by focusing on internal medicine, obstetrics and gynecology, and urology as its key therapeutic areas.
As a pioneer in hormone preparations, the Company holds more than 90% of the domestic market share in the thyroid area, mainly with THYRADIN S tablet. In recent years, we have also been committed to strengthening our product lineup to become a leading company in obstetrics and gynecology, which we have been engaged in since our founding.
ASKA Pharmaceutical holds over 90% of the domestic market share in the thyroid field with its thyroid hormone agent THYRADIN S Tablets.
In September 2014, we were the first to pre-launch authorized generics in Japan.
In November 2016, we also launched Japan's
only poorly absorbable antibacterial drug indicated for the improvement of hyperammonemia in hepatic encephalopathy.
In March 2019, we launched Japan's first once-daily oral GnRH antagonist agent indicated for the improvement of excessive menstruation, lower abdominal pain, back pain, and anemia based on uterine fibroids.
Optimal Value Chain Derived from DNA Rooted in Corporate Culture
A value chain penetrated with DNA is the source of ASKA Pharmaceutical's impressive growth.
ASKA Pharmaceutical's DNA is "As a pioneer of hormone preparations, we have a mission to deliver valuable pharmaceutical products as long as there is a medical need for them. In the past, present, and future, this DNA has taken root in each employee in our value chain (research, development, sales, production, quality assurance, etc.). It drives us to take on the challenge of meeting medical needs. Every one of our employees will keep this DNA in their hearts as their strength, aiming to create the value that only ASKA Pharmaceutical can offer.
Contribution to the Obstetrics and Gynecology Field
Supporting the vibrant advancement of women by contributing to the field of obstetrics and gynecology
We pharmaceutical companies face various challenges in the environment surrounding us, such as the declining birthrate and aging population, promotion of women's activities, expansion of medical expenses, and response to unmet medical needs*. Amid these challenges, ASKA Pharmaceutical, as a pioneer of hormone preparations, fulfills its mission by leveraging its presence in the field of obstetrics and gynecology, which it has developed over the years, to enhance its presence as a specialty pharma company that supports the improvement of the quality of life (QOL) of women in particular.
*Unmet medical needs = medical needs that have not yet been met